» Articles » PMID: 17409456

A High-throughput Study in Melanoma Identifies Epithelial-mesenchymal Transition As a Major Determinant of Metastasis

Abstract

Metastatic disease is the primary cause of death in cutaneous malignant melanoma (CMM) patients. To understand the mechanisms of CMM metastasis and identify potential predictive markers, we analyzed gene-expression profiles of 34 vertical growth phase melanoma cases using cDNA microarrays. All patients had a minimum follow-up of 36 months. Twenty-one cases developed nodal metastatic disease and 13 did not. Comparison of gene expression profiling of metastatic and nonmetastatic melanoma cases identified 243 genes with a >2-fold differential expression ratio and a false discovery rate of <0.2 (206 up-regulated and 37 down-regulated). This set of genes included molecules involved in cell cycle and apoptosis regulation, epithelial-mesenchymal transition (EMT), signal transduction, nucleic acid binding and transcription, protein synthesis and degradation, metabolism, and a specific group of melanoma- and neural-related proteins. Validation of these expression data in an independent series of melanomas using tissue microarrays confirmed that the expression of a set of proteins included in the EMT group (N-cadherin, osteopontin, and SPARC/osteonectin) were significantly associated with metastasis development. Our results suggest that EMT-related genes contribute to the promotion of the metastatic phenotype in primary CMM by supporting specific adhesive, invasive, and migratory properties. These data give a better understanding of the biology of this aggressive tumor and may provide new prognostic and patient stratification markers in addition to potential therapeutic targets.

Citing Articles

The role of ESRP1 in solid tumor development through the regulation of CD44 splicing and EMT processes.

Wang L, Zhang M, Zhao K, Yuan X, Zhao H, Liu Y Front Oncol. 2025; 15:1451130.

PMID: 40046628 PMC: 11881191. DOI: 10.3389/fonc.2025.1451130.


Long non-coding RNA GRASLND links melanoma differentiation and interferon-gamma response.

Fischer K, Tiwari S, Thier B, Qiu L, Lin T, Paschen A Front Mol Biosci. 2024; 11:1471100.

PMID: 39398277 PMC: 11466874. DOI: 10.3389/fmolb.2024.1471100.


The classification of melanocytic gene signatures.

Hu M, Coleman S, Judson-Torres R, Tan A Pigment Cell Melanoma Res. 2024; 37(6):854-863.

PMID: 39072997 PMC: 11518649. DOI: 10.1111/pcmr.13189.


Dormancy of cutaneous melanoma.

Singvogel K, Schittek B Cancer Cell Int. 2024; 24(1):88.

PMID: 38419052 PMC: 10903048. DOI: 10.1186/s12935-024-03278-5.


The Use of Gene Expression Profiling and Biomarkers in Melanoma Diagnosis and Predicting Recurrence: Implications for Surveillance and Treatment.

Sun J, Karasaki K, Farma J Cancers (Basel). 2024; 16(3).

PMID: 38339333 PMC: 10854922. DOI: 10.3390/cancers16030583.